CONNECT WITH US:
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer's Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
Oct 23, 2019 10:13 JST
Biogen and Eisai, Co., Ltd. has announced that, after consulting with the U.S. Food and Drug Administration (FDA), Biogen plans to pursue regulatory approval for aducanumab, an investigational treatment for early Alzheimer's disease (AD).
Eisai's New Drug Approval for Fycompa for Adjunctive Treatment of Partial Onset Seizures in China
Oct 15, 2019 20:24 JST
Eisai Co., Ltd. has announced that Eisai received a New Drug Approval for its in-house discovered and developed antiepileptic drug (AED) Fycompa (perampanel) from the China National Medical Products Administration (NMPA) for use in an adjunctive treatment of partial onset seizures (with or without secondarily generalized seizures) in epilepsy patients 12 years of age and older.
Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
Oct 01, 2019 10:46 JST
The findings were presented in a proffered paper presentation at the European Society for Medical Oncology (ESMO) 2019 Congress (Abstract #994O).
Eisai and Nichi-Iko Enter into Collaboration Agreement for Generic Pharmaceutical Business in China
Sep 30, 2019 11:06 JST
Eisai Co., Ltd. and Nichi-Iko Pharmaceutical have entered into a comprehensive collaboration agreement for the generic pharmaceutical business in China.
Eisai and Tokio Marine Nichido Enter Into Business Alliance for Co-Existence and Prevention of Dementia
Sep 26, 2019 13:21 JST
Eisai Co., Ltd. and Tokio Marine & Nichido Fire Insurance Co., Ltd. announced today that the companies have entered into a business alliance agreement for co-existence and prevention of dementia.
Eisai and Fronteo to Launch Coroban Tumbling and Falling Prediction System for Inpatients
Sep 26, 2019 13:08 JST
Eisai Co., Ltd. and FRONTEO, Inc. announced today that they have launched the tumbling and falling prediction system Coroban to medical institutions in Japan on September 26, 2019.
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2019 Congress
Sep 24, 2019 09:01 JST
Eisai Co., Ltd. announced today that a series of abstracts will be presented during the European Society for Medical Oncology (ESMO) 2019 Congress taking place in Barcelona, Spain, from September 27 to October 1, 2019.
Eisai and Meiji Announce Parkinson's Disease Treatment Equfina Tablets (Safinamide Mesilate) Approved In Japan
Sep 20, 2019 15:13 JST
In Japan, Meiji holds the manufacturing and marketing approval for safinamide, and Eisai exclusively sells the safinamide.
Eisai's Promotion and Distribution Agreement with Mylan India for Eribulin Second Brand in India
Sep 20, 2019 08:40 JST
Eisai Co., Ltd. has announced that Eisai's subsidiary Eisai Pharmaceuticals India Pvt. Ltd. and Mylan N. V. subsidiary Mylan India have entered into a license agreement to promote and distribute the second brand TECERIS for the anticancer agent eribulin mesylate (eribulin) in India.
Eisai to Present Latest Data on Lemborexant at World Sleep Congress
Sep 19, 2019 19:06 JST
Eisai Co., Ltd. has announced that latest data on lemborexant, an investigational sleep-wake regulation agent being studied for the treatment of sleep-wake disorders, including insomnia and Irregular Sleep-Wake Rhythm Disorder (ISWRD) associated with Alzheimer's disease/dementia will be presented at World Sleep Congress (World Sleep 2019), from September 20 to 25 in Vancouver, Canada.
Eisai Selected for Membership in Dow Jones Sustainability Asia Pacific Index 2019
Sep 18, 2019 20:40 JST
Eisai Co., Ltd. has been selected for a membership in the Dow Jones Sustainability Asia Pacific Index (DJSI Asia Pacific), the Asia Pacific version of the Dow Jones Sustainability Indices (DJSI), which are a family of premier global indices for socially responsible investment (SRI).
FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
Sep 18, 2019 13:58 JST
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) approved the combination of LENVIMA, the orally available kinase inhibitor discovered by Eisai, plus KEYTRUDA, Merck & Co., Inc., Kenilworth, N.J., U.S.A.'s anti-PD-1 therapy.
Eisai Receives IIA Japan Chairman's Award of Institute of Internal Auditors - Japan
Sep 17, 2019 15:42 JST
Eisai Co., Ltd. has announced that it received the 33rd "IIA Japan Chairman's Award" of the Institute of Internal Auditors - Japan.
Eisai and Biogen to Discontinue Phase III Clinical Studies of Bace Inhibitor Elenbecestat in Early Alzheimer's Disease
Sep 13, 2019 17:43 JST
Eisai Co., Ltd and Biogen Inc. today announced the decision to discontinue the Phase III clinical studies (MISSION AD1, AD2) on the investigational oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat (development code: E2609) in patients with early Alzheimer's disease (AD).
Eisai to Launch New "Etak Antimicrobial Wet Wipes" With One Week Lasting Antimicrobial Action
Aug 29, 2019 10:46 JST
Eisai Co., Ltd. will launch ETAK( Antimicrobial Wet Wipes (classified as miscellaneous goods) containing long-acting antimicrobial agent ETAK on August 29, 2019 at pharmacies and drugstores countrywide.
Eisai Enters Into Business Alliance With Cogstate for Exclusive Development and Commercialization of a Digital Tool for Self-Assessment of Cognitive Function in Japan
Aug 28, 2019 09:58 JST
Eisai Co., Ltd. has entered into a business alliance agreement for exclusive development and commercialization of a cognitive function test - Cogstate Brief Battery (CBB) - developed by Cogstate Ltd., in Japan as a digital tool for self-assessment of cognitive function (classified as miscellaneous goods).
Eisai Provides Tanks to Supply Clean Water to Neglected Tropical Diseases Endemic Regions in Kenya, in Collaboration With Merck
Aug 27, 2019 11:37 JST
Eisai Co., Ltd. announced that it provides tanks to supply clean water for the neglected tropical diseases (NTDs) measuresto the endemic regions in Kenya in collaboration with Merck.
Eisai to Refresh and Launch Sahne Cream After 20 Years with Mild Scent and New Package
Aug 01, 2019 10:41 JST
Eisai Co., Ltd. announced today that it refresh its SAHNE CREAM (quasi-drug) which has been widely used as medical skin care, for the first time in 20 years, and launch at pharmacies and drug stores in Japan on today August 1, 2019.
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA
Jul 23, 2019 11:37 JST
This is the third Breakthrough Therapy designation for the LENVIMA plus KEYTRUDA combination.
Eisai Presented Latest Trends of Treatment for Alzheimer's at AAIC 2019
Jul 19, 2019 12:00 JST
Eisai Co.,Ltd. announced the presentation and discussion about the treatment, including oral beta amyloid cleaving enzyme (BACE) inhibitor elenbecestat research data on Alzheimer's disease(AD).
Eisai Presented Data Showing Quantification of Tau Microtubule Binding Region at AAIC 2019
Jul 19, 2019 08:15 JST
Eisai Co.,Ltd. announced that data relating to a new anti-tau antibody E2814(1) was presented at the Alzheimer's Association International Conference (AAIC) held in Los Angeles, California, United States, from July 14 to 18, 2019 (Poster Presentation No.: P4-696).
Eisai Presents Research Evaluating Correlation of Highly-Precisely Measured Amyloid Beta in Plasma and Cerebrospinal Fluid with Newly Developed Automated Protein Assay System at AAIC 2019
Jul 18, 2019 13:26 JST
Eisai Co.,Ltd. announced its latest research on evaluation about correlation of amyloid beta (Abeta) in plasma and in cerebrospinal fluid (CSF) by high precision measurement with the newly developed automated protein assay system, jointly developed with Sysmex Corporation.
Eisai Presents Nonclinical Research Results of Elenbecestat at AAIC 2019
Jul 18, 2019 12:01 JST
Eisai Co.,Ltd. announced its latest data of nonclinical research which examined the effect to the synaptic function in the brain by spinal densities in regard to oral BACE (beta-site amyloid precursor protein cleaving enzyme) inhibitor elenbecestat were presented at AAIC.
Eisai's Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China
Jul 17, 2019 08:20 JST
Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate) for use in the treatment of patients with locally advanced or metastatic breast cancer, previously treated with at least two prior chemotherapy regimens, including an anthracycline and a taxane, from the China National Medical Products Administration (NMPA).
Eisai Listed for 18th Consecutive Year in FTSE4Good Index Series
Jul 11, 2019 12:59 JST
Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 18th consecutive year since its initial inclusion in 2002.
Latest Data on Eisai's Alzheimer's Disease/ Dementia Pipeline to be Presented at AAIC 2019
Jul 11, 2019 09:04 JST
Eisai Co., Ltd. announced today that a total of 13 presentations containing two oral presentations including the latest data of the anti-amyloid beta (A beta) protofibril antibody BAN2401 and the oral BACE (beta amyloid cleaving enzyme) inhibitor elenbecestat, will be given at the Alzheimer's Association International Conference (AAIC) 2019..
Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts
Jul 10, 2019 12:27 JST
Eisai Co., Ltd. has announced that the Eisai Center for Genetics Guided Dementia Discovery (G2D2), a new exploratory research facility in Cambridge, Massachusetts, U.S., held its opening ceremony and has begun full-scale research activities.
Eisai Enters Into Collaboration Research Agreement With University of Dundee on Targeted Protein Degradation Toward Cancer Drug Discovery
Jul 08, 2019 09:31 JST
Eisai Co.,Ltd. has entered into a collaboration research agreement with the University of Dundee in Scotland, UK, regarding Proteolysis Targeting Chimeras (PROTACs)(1) toward drug discovery in oncology area.
Eisai: Total Synthesis and Nonclinical Study Results of a Novel Anticancer Drug Candidate E7130
Jun 18, 2019 12:32 JST
Eisai Co., Ltd. announced today that a joint research group including scientists from Eisai and Professor Yoshito Kishi's group of Harvard University has achieved a total synthesis and obtained results of nonclinical studies of the novel compound, E7130, derived from total synthesis of halichondrin.
MITSUBISHI MOTORS' eK X & eK Wagon Kei Cars Win RJC Car of the Year 2020
Nov 13, 2019 19:39 JST
MHI Aero Engines Makes First Shipment of Domestically Assembled Pratt & Whitney GTF PW1200G Engine for the Mitsubishi SpaceJet
Nov 13, 2019 16:01 JST
Fujitsu Launches New PRIMEHPC Supercomputers Using Fugaku Technology
Nov 13, 2019 10:37 JST
Cray and Fujitsu Partner to Power Supercomputing in the Exascale Era
Nov 13, 2019 10:02 JST
MITSUBISHI MOTORS Introduces XPANDER CROSS
Nov 12, 2019 18:01 JST
DENSO Recognized with "Friend of ASEAN Award" at the ASEAN Business Awards (ABA) 2019
Nov 11, 2019 17:07 JST
Lexus Electric Debuts in China
Nov 11, 2019 16:38 JST
Fujitsu Expands Mid-career Recruitment
Nov 11, 2019 10:33 JST
Double Shanghai Podium for TOYOTA GAZOO Racing
Nov 11, 2019 09:11 JST
TOYOTA GAZOO Racing goes all-in for another title in Australia
Nov 08, 2019 19:33 JST
Honda Releases Consolidated Financial Summary for the Fiscal 2nd Quarter Ended September 30, 2019
Nov 08, 2019 15:09 JST
Mitsubishi Model A Selected as Historic Car by JAHFA
Nov 08, 2019 14:49 JST
BYD, Toyota Agree to Establish Joint Company for Battery Electric Vehicle Research and Development
Nov 07, 2019 19:12 JST
MITSUBISHI MOTORS Restyles Mirage and Attrage Compact Models
Nov 07, 2019 11:58 JST
Hitachi and Centre Leon Berard Cancer Center in Lyon to Launch a Research Collaboration in the Fight Against Cancer with AI
Nov 07, 2019 07:25 JST
Fujitsu Improves Efficiency in Cancer Genomic Medicine in Joint AI Research with the Institute of Medical Science at the University of Tokyo
Nov 07, 2019 05:09 JST
ULVAC launches Smartphone-Direct Pirani Gauge "SWU10-U"
Nov 06, 2019 17:00 JST
Showa Denko (SDK) Announces 2019 Third Quarter Financial Results
Nov 06, 2019 16:00 JST
NEC Showcases Industry-leading Digital Finance Solutions at Inaugural SFF X Switch 2019
Nov 06, 2019 15:11 JST
Suzhou Tongji Blockchain Research Institute and Fujitsu Research and Development Center start Research Collaboration on Blockchain Technology
Nov 06, 2019 11:45 JST
More Latest Release >>